Moreover, SFN and EGCG co-administration suppressed the growth of ovarian cancer cells, caused G2/M cell cycle arrest, and induced apoptosis in SKOV3TR-ip2 cells (paclitaxel-resistant ovarian cancer cell line) by increasing the down-regulation of Bcl-2, hTERT, and PARP cleavage [176]. The gene discussed is BCL2; the disease is ovarian carcinoma.